Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

3.52  +0.06 (+1.73%)

After market: 3.59 +0.07 (+1.99%)

Fundamental Rating

4

Overall RLAY gets a fundamental rating of 4 out of 10. We evaluated RLAY against 555 industry peers in the Biotechnology industry. RLAY has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, RLAY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RLAY has reported negative net income.
RLAY had a negative operating cash flow in the past year.
In the past 5 years RLAY always reported negative net income.
In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -41.71%, RLAY perfoms like the industry average, outperforming 55.32% of the companies in the same industry.
RLAY's Return On Equity of -46.23% is fine compared to the rest of the industry. RLAY outperforms 67.03% of its industry peers.
Industry RankSector Rank
ROA -41.71%
ROE -46.23%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RLAY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
RLAY has more shares outstanding than it did 1 year ago.
RLAY has more shares outstanding than it did 5 years ago.
RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

RLAY has an Altman-Z score of 0.92. This is a bad value and indicates that RLAY is not financially healthy and even has some risk of bankruptcy.
RLAY has a Altman-Z score of 0.92. This is in the better half of the industry: RLAY outperforms 65.95% of its industry peers.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.92
ROIC/WACCN/A
WACC8.93%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

RLAY has a Current Ratio of 19.96. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 19.96, RLAY belongs to the best of the industry, outperforming 93.51% of the companies in the same industry.
A Quick Ratio of 19.96 indicates that RLAY has no problem at all paying its short term obligations.
The Quick ratio of RLAY (19.96) is better than 93.51% of its industry peers.
Industry RankSector Rank
Current Ratio 19.96
Quick Ratio 19.96
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.53% over the past year.
The Revenue for RLAY has decreased by -87.39% in the past year. This is quite bad
RLAY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.92% yearly.
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)-87.39%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%-23.26%

3.2 Future

RLAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.25% yearly.
The Revenue is expected to grow by 54.93% on average over the next years. This is a very strong growth
EPS Next Y20.6%
EPS Next 2Y10.36%
EPS Next 3Y6.89%
EPS Next 5Y10.25%
Revenue Next Year-27.83%
Revenue Next 2Y-18.35%
Revenue Next 3Y6.86%
Revenue Next 5Y54.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.36%
EPS Next 3Y6.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RLAY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (7/1/2025, 6:57:39 PM)

After market: 3.59 +0.07 (+1.99%)

3.52

+0.06 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners88.43%
Inst Owner Change4.68%
Ins Owners1.51%
Ins Owner Change1.74%
Market Cap603.47M
Analysts84.21
Price Target14.79 (320.17%)
Short Float %16.13%
Short Ratio11.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.52%
Min EPS beat(2)7.59%
Max EPS beat(2)21.46%
EPS beat(4)4
Avg EPS beat(4)14.07%
Min EPS beat(4)7.59%
Max EPS beat(4)21.46%
EPS beat(8)8
Avg EPS beat(8)14.85%
EPS beat(12)9
Avg EPS beat(12)9.47%
EPS beat(16)10
Avg EPS beat(16)-14.69%
Revenue beat(2)1
Avg Revenue beat(2)37542.2%
Min Revenue beat(2)-100%
Max Revenue beat(2)75184.3%
Revenue beat(4)1
Avg Revenue beat(4)18721.1%
Min Revenue beat(4)-100%
Max Revenue beat(4)75184.3%
Revenue beat(8)3
Avg Revenue beat(8)11727.8%
Revenue beat(12)4
Avg Revenue beat(12)7798.91%
Revenue beat(16)6
Avg Revenue beat(16)5879.62%
PT rev (1m)-14.71%
PT rev (3m)-27.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.54%
EPS NY rev (1m)1.75%
EPS NY rev (3m)16.94%
Revenue NQ rev (1m)-10%
Revenue NQ rev (3m)-98.01%
Revenue NY rev (1m)20.42%
Revenue NY rev (3m)218.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.59
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.04
BVpS4.21
TBVpS4.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.71%
ROE -46.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.79%
Cap/Sales 8.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.96
Quick Ratio 19.96
Altman-Z 0.92
F-Score3
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y20.6%
EPS Next 2Y10.36%
EPS Next 3Y6.89%
EPS Next 5Y10.25%
Revenue 1Y (TTM)-87.39%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%-23.26%
Revenue Next Year-27.83%
Revenue Next 2Y-18.35%
Revenue Next 3Y6.86%
Revenue Next 5Y54.93%
EBIT growth 1Y42.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.6%
EBIT Next 3Y3.6%
EBIT Next 5Y13.4%
FCF growth 1Y-6.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.92%
OCF growth 3YN/A
OCF growth 5YN/A